This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Campus
  1. Event
  2. Source: Campus Sanofi
  3. 13 Mar 2024
15 min

WORLD Symposium 2024 Re-Cap

Author: Sanofi

This is intended for HCPs practising in Great Britain (England, Scotland and Wales) only.
Prescribing Information can be found at the bottom of this page

Clinical outcomes in patients switching from agalsidase beta to migalastat

Speaker: Dr Karolina Stepien (Consultant Metabolic Specialist, Salford Royal Hospital)

Poster covered: Clinical outcomes in patients switching from agalsidase beta to migalastat: a Fabry Registry analysis. 

Stroke in patients with Fabry
Disease: A Fabry Registry
analysis

Speaker: Dr David Moreno Martinez (Consultant Metabolic specialist, Royal Free Hospital, London)

Poster covered: Stroke in patients with Fabry disease: A Fabry Registry analysis of natural history data from patients stratified by disease phenotype.

Pivotal Pompe Posters and Symposia

Speaker: Prof Mark Roberts (Consultant Neurologist and Research Lead, Salford Royal NHS Foundation Trust)

Topics covered:

  • Real-world experience of switching treatments from Myozyme (alglucosidase alfa) to
    Nexviadyme    ▼(avalglucosidase alfa) for patients enrolled in the Pompe registry
  • COMET Post Hoc Analysis
  • Efficacy of Long-Term Avalglucosidase Alfa in Subgroups of Participants with Late-Onset Pompe Disease and From Bench to Bedside: the example of Pompe disease (a Sanofi-sponsored symposia)

Abstract summary of WORLD Symposia 'Gaucher disease Symposium and Long term safety outcomes of eliglustat in patients with Gaucher disease

Speaker: Dr Karolina Stepien (Consultant Metabolic Specialist, Salford Royal Hospital)

Poster covered:

  • Abstract summary of WORLD Symposia 'Gaucher disease Symposium: A Focus on Bone Manifestations in Gaucher Disease Type 1 Patients'
  • Long term safety outcomes of Cerdelga▼(eliglustat) in patients with Gaucher disease: prospective, multi-center, observational, post-authorization safety sub-registry study

Prescribing Information

Nexviadyme®
(avalglucosidase alfa)

Fabrazyme®
(agalsidase beta)

Cerdelga®
(hard capsules eliglustat)

Myozyme
(alglucosidase alfa) 

MAT-XU-2400942 (v1.0) Date of Preparation April 2024